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Abstract
Purpose Conventional Abrams biopsy shows low sensi-
tivity in suspected malignant pleural disease. There are
limited data on the improvement in sensitivity by adding in
image guidance. This retrospective study compares the
diagnostic sensitivity of Abrams biopsy using ultrasound
guidance with CT-guided Tru-Cut biopsy in suspected
malignant pleural disease.
Methods Data were collected from 2006 to 2012 of
patients who underwent image-guided biopsies for sus-
pected non-tuberculous pleural disease. Data were col-
lected on the result of the initial biopsy and final patient
diagnosis as of June 2015.
Results Sixty-three patients underwent image-guided
Abrams biopsy and 29 underwent CT-guided Tru-Cut
biopsies. The sensitivity of Abrams was 71.43 % compared
to 75 % in the CT-guided Tru-Cut group. Specificity was
100 % in both groups.
Conclusions Image-guided Abrams biopsies demonstrate
comparable diagnostic sensitivity in malignant pleural
disease to CT-guided Tru-Cut biopsy.
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Introduction
There are more than sixty recognised causes for pleural
effusion. Pleural fluid biochemistry and cytology are often
the first invasive test. In suspected malignant pleural dis-
ease, diagnostic thoracocentesis offers a positive cytolog-
ical diagnosis in 50–60 % of cases [1], with a sequential
gain of 27–31 % from a repeat procedure [2]. If pleural
fluid cytology is negative, histology is necessary to estab-
lish the diagnosis. Thoracoscopic pleural biopsy remains
the gold standard with a diagnostic yield of up to 99 %
[3–5]. However, patients need to be sufficiently fit enough
to undergo either video-assisted thoracoscopic surgery or
local anaesthetic ‘‘medical’’ thoracoscopy. Percutaneous
pleural biopsy is a less invasive alternative, particularly
indicated when pleural malignancy or tuberculosis is
suspected.
Historically closed pleural biopsies are mostly per-
formed using an Abrams needle or Tru-Cut needle. Abrams
needles are reversed bevelled punch biopsy needles that
allow tissue sampling to be performed as a day case in a
dedicated procedural area or at the bedside depending on
local practice. When performed in the traditional sense as a
‘‘blind’’ procedure, the diagnostic sensitivity in malignant
disease is variable (between 40 and 73 % [6–8]). Although
real-time visualisation with ultrasound (US) whilst using
Abrams needle is not possible, it can be used to direct site
selection during the procedure, increasing yield to
60–77.4 % [9]. Incorporating CT guidance to target areas
of pleural disease has been shown to increase the sensi-
tivity to 87.5 % [10].
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Percutaneous CT-guided Tru-Cut cutting needle biop-
sies are considered a superior diagnostic method. These are
typically performed by radiologists. The diagnostic sensi-
tivity in malignant disease is consistently superior to blind
Abrams biopsy at approximately 87 % [6, 11].
There are no studies comparing ultrasound-guided
Abrams to CT-guided Tru-Cut biopsies in malignant
pleural disease. We hypothesise that ultrasound-directed
percutaneous Abrams biopsies will produce comparable
results to CT-guided Tru-Cut biopsy. We retrospectively
evaluated both approaches, following up patients over
3 years to assess the sensitivity of these diagnostic
modalities in suspected malignant disease.
Materials and Methods
As a retrospective service evaluation, written patient
informed consent and regional ethics approval were not
required. Local clinical governance committee approval was
needed for the use of patient records, which was obtained.
Using radiology and pleural clinic databases, we identified
all patientswhounderwent aCT-guidedTru-Cut pleural biopsy
or US-guided Abrams pleural biopsy for suspected non-tuber-
culous pleural disease with no cytological diagnosis on previ-
ous fluid aspirate from February 2005 to September 2012 at
Guys and St Thomas’ NHS Foundation Trust. We reviewed
hospital inpatient documentation, radiological reports, clinic
letters, cytological, and histological results. All procedures
were performed on an outpatient basis, unless the patient had
already been admitted to hospital. Patients with suspected or
proven granulomatous disease were excluded. Suspicion of
granulomatous disease was defined as clinical and/or radio-
logical features highly suggestive of pulmonary or extrapul-
monary tuberculosis in the absence of positive microbiological
confirmation at the time of pleural biopsy.
Abrams Biopsy
This is performed in a designated area in an outpatient
setting by a trained and experienced consultant and
supervised specialist registrars. Ultrasound image guidance
is employed to identify sites of pleural abnormality. Under
local anaesthesia, closed pleural biopsies are then per-
formed using a reverse-bevelled Abram biopsy needle.
CT-Guided Tru-Cut Needle Biopsy
Cases are vetted at radiology meetings based on their
amenability to biopsy. These are performed under local
anaesthesia by trained interventional radiologists. CT is used to
directly visualise and target the biopsy site with a Tru-Cut
cutting needle.
We recorded the histological result of the initial biopsy in
both groups. The standard employed to determine diagnostic
accuracywas a final diagnosis ofmesothelioma ormetastatic
pleural malignancy made up to September 2015 or at death
(whichever came sooner). If a patient died within the follow-
up period, clinical notes were reviewed to ascertain if a
cancer diagnosis was made at the time of death. The volume
of biopsy specimens was attained from the histology reports.
Data on subsequent pleural procedures were also recorded.
Statistical analyses were performed using IBM SPSS
version 22. Continuous data are summarised as mean with
standard deviation (for normally distributed data) or med-
ian with 25–75 % interquartile range (for data with a
skewed distribution). Binary data are presented as per-




During the study period 63 patients underwent Abrams
biopsy and 29 patients underwent CT-guided biopsy for
suspected non-tuberculous pleural disease (Table 1). Final
cancer diagnoses are available in supplementary table S1.
In the US Abrams group (Fig. 1), malignancy was
identified in 25 (39.6 %) patients from the initial biopsy.
Biopsies were non-diagnostic (no pleural tissue) in two
cases. The remaining 36 (57.1 %) had either normal his-
tology or was consistent with a benign process. One of
these patients was deemed unfit for further investigation
and given a clinical diagnosis of pleural malignancy and
two patients had concurrent fluid cytology consistent with
malignancy. Sixteen of these patients had subsequent
procedures with six histological and one clinical diagnosis
of malignancy made. Of 17 patients that underwent regular
follow-up, all either remained well or died within the fol-
low-up period of a non-malignant cause. Including those
patients with a clinical diagnosis of malignancy, the overall
sensitivity of ultrasound-guided Abrams needle biopsy is
71.4 %, specificity 100 % with a positive predictive value
of 100 % and negative predictive value of 72.2 %.
Of the 25 initial Abrams biopsies malignancy, concur-
rent cytology was available in 23 cases. Thirteen (56.5 %)
concurrent samples demonstrated positive cytology con-
firming malignant cells with 10 (43.5 %) cases failing to
yield the diagnosis.
In the CT Tru-Cut group (Fig. 2), malignancy was
identified in 15 (68.8 %) patients. Biopsy was non-diag-
nostic in two (6.3 %) cases. Both patients underwent fur-
ther sampling demonstrating malignant disease. Twelve
(41.4 %) patients had histology consistent with benign
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disease, five of which underwent a repeat procedure
yielding a malignant diagnosis. Four remained well with no
diagnosis of malignant disease during the follow-up period.
One patient was discharged to a nursing home and lost to
further follow-up. Two patients died secondary to a non-
malignant cause. Assuming the patient lost to follow-up
had a final diagnosis of a benign condition, the sensitivity
of CT-guided Tru-Cut biopsy is 75 %, specificity 100 %
with a positive predictive value of 100 %, and negative
predictive value of 58.3 %. The radiology appearances of
pleural disease targeted in the CT biopsy group can be
found in supplementary table S2.
Biopsy Specimen Size
Data were available on the 86 individual biopsy specimens
in the Abrams group vs 56 in the Tru-Cut group (Table 2
and Fig. 3).
Discussion
Our retrospective evaluation shows that ultrasound-di-
rected Abrams biopsy offers superior sensitivity compared
to published data with the conventional ‘‘blind’’ approach
Table 1 Patient demographics and diagnostic yield in the two groups
Ultrasound-guided Abrams group CT-guided Tru-Cut group
Number of patients 63 29
Male 39 (61.9 %) 19 (65.5 %) Chi square p = 0.739
Age (years), mean (SD) 64.4 (15.97) 69 (15.22) Independent t p = 0.196
Diagnosis on initial biopsy Chi square p = 0.326
Malignancy 25 (39.7 %) 15 (51.7 %)
Benign/alternative diagnosis 36 (57.1 %) 12 (41.4 %)
Non-diagnostic/no pleural tissue 2 (3.0 %) 2 (6.9 %)
Final diagnosis at 3 years Chi square p = 0.316
Malignancy 33 (?2 clinical diagnoses) (55.6 %) 22 (75.9 %)
Benign 28 (44.4 %) 6 (20.7 %)
Unknown – 1* (3.4 %)
Overall sensitivity 71.43 % 75 %
* This patient was discharged to a nursing home following the biopsy and lost to further follow-up
Fig. 1 Diagnostic pathway of the patients in the US-guided Abrams biopsy group. Shaded boxes represent a diagnosis of malignant or benign
disease at the end of the follow-up period (VATS video-assisted thoracoscopic surgery)
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[6]. The use of image guidance is the only difference in our
series increasing the diagnostic yield versus the published
literature. A considerable proportion of those with a posi-
tive Abrams biopsy had concurrent negative cytology,
suggesting that image-guided biopsies may be useful in
patients with negative cytology. It also demonstrates
comparable sensitivity to the CT group, the performance of
which is slightly poorer than published data where the
diagnostic yield is quoted as 87 % [12]. A possible
explanation is that in our tertiary centre, patients referred
for CT biopsy are highly selected, with the radiological
feature of pleural nodularity which may prove challenging
to access percutaneously.
Thoracic ultrasound is a useful tool in malignant disease
which may allow further visualisation and targeting of
disease. One study was able to identify 73 % of malignant
effusions on US appearance alone with pleural thickening
[10 mm, pleural nodularity and diaphragmatic thickening
[7 mm highly suggestive of malignant disease [13].
Ultrasound may also be used with Tru-Cut needle biopsies
with the advantage of real-time visualisation (as opposed to
US-directed site selection with an Abrams needle). Incor-
porating ultrasound increases the diagnostic yield in
malignancy of the Tru-Cut needle to between 70 and
85.5 % [14, 15] compared to 54 % with a blind approach
[16]. With growing US expertise amongst respiratory
Fig. 2 Diagnostic pathway of patients in the CT-guided Tru-Cut group. Shaded boxes represent a diagnosis of malignant or benign disease at the
end of the follow-up period (VATS video-assisted thoracoscopic surgery)
Table 2 Volume of biopsy samples in the two groups
US-guided Abrams group CT-guided Tru-Cut group
Number of biopsy samples 86 56
Median volume (mm3) 18 (IQR 16–60) 7.1 (IQR 3.1–8.0) Mann–Whitney U p\ 0.001
Fig. 3 Box plot of biopsy volumes in the Abrams and Tru-Cut groups
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physicians, it has shown to be safe in the hands of respi-
ratory physicians for lesions greater than 20 mm in
diameter.
Biopsy volume was significantly larger in the Abrams
group. A possible explanation for this is that the Abrams
needle used in our case series is eight gauge versus the
commonly used Tru-Cut needle sizes between 16 and 19
gauge used in our institute. Although the volume of tissue
is significantly lower in the Tru-Cut group, the real-time
image guidance afforded in this technique may allow
focused targeting of pleural tissue resulting in a satisfactory
diagnostic yield. This is also reflected in a study by
Koegelenberg et al. which suggests a comparable yield in
pleural malignancy between US-guided Abrams and US
Tru-Cut biopsies [17].
These results should be interpreted with caution given
significant selection bias in our data. The decision of the
biopsy technique employed was taken by the physician in a
centre with a dedicated pleural service based on clinical
data, point of care ultrasound findings, experience and
expertise. Those referred for CT biopsy had either minimal
effusions (which would preclude the use of Abrams) or a
target area not easily identifiable on ultrasound. Cases are
also vetted by radiologists resulting in a narrowly selected
group of patients. It is also reasonable to assume that those
with disease that is difficult to access percutaneously or no
focal pleural abnormality would undergo an alternative
diagnostic pathway.
The strength of our study is the 3-year follow-up period,
which will reduce the false-negative rate. To our knowl-
edge, there are no published data on long-term follow-up
investigating the false-negative rate following image-gui-
ded biopsies. It also has real world applicability, especially
as the population studied has followed a pathway where the
choice of biopsy technique depends heavily on the clinical
and radiological picture.
Conclusion
Image-guided pleural biopsy is useful in the diagnostic
workup of a selected group of patients with suspected non-
tuberculous pleural disease. A larger prospective trial is
needed for a more definitive answer. Although one single
technique may not be suitable for all patients, a satisfac-
tory diagnostic yield is achieved if the biopsy method is
selected based on clinical and radiological amenability, as
well as operator experience and confidence.
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